HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

61.800

0.000

Volume:- -

Turnover:- -

Market Cap:10.51B

PE:-29.43

High:61.800

Open:61.800

Low:61.800

Close:61.800

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:5.21

PE(LYR):-29.43

PS:19.41

Loading ...

Overview Company News Filings

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism

Bulletin Express

Suzhou Ribo submits EMA Phase 2b trial application for vortosiran in VTE

RIBOLIFE-B Maintains 170.55 Million Issued Shares in April; Confirms Public Float Compliance

Bulletin Express

Ribo, Boehringer advance siRNA MASH drug program to third milestone

Ribo and Boehringer Ingelheim Further Progress Their Sirna Program for Metabolic Dysfunction-Associated Steatohepatitis (Mash)

THOMSON REUTERS

Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations

RIBOLIFE-B Achieves Key Development Milestone in Liver Disease Collaboration with Boehringer Ingelheim

Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim

Bulletin Express

Suzhou Ribo hits third research milestone in Boehringer liver disease collaboration

RIBOLIFE-B聚焦创新药管线，2025年营收小幅增长但仍录净亏损

Bulletin Express

Suzhou Ribo Life Science publishes 2025 annual report

RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention

RIBOLIFE-B (06938) Submits Application for Phase 2b Trial of Core Product VORTOSIRAN in SPAF Indication

Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF

RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised

Bulletin Express

China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026

Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives

Simply Wall St.

RIBOLIFE-B (06938) Proposes Adoption of H Share Option Scheme and H Share Incentive Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/06938/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":61.8,"timestamp":1788138006109,"preClose":61.8,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Pre-opening","change":0,"latestTime":"08-31 09:12:21","open":61.8,"high":61.8,"low":61.8,"amount":0,"amplitude":0,"askPrice":67,"askSize":400,"bidPrice":58.1,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.149,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":1,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61.8,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"shares":170000000,"dividePrice":0,"high":61.8,"amplitude":0,"preClose":61.8,"low":61.8,"week52Low":43.6,"pbRate":"5.21","psRate":"19.41","week52High":95.8,"institutionHeld":0,"latestPrice":61.8,"committee":0.666667,"eps":-2.100221,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.149,"open":61.8,"prevYearClose":57.97,"fiveDayClose":61.4,"twentyDayClose":46.64,"sixtyDayClose":55.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784304000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-08-28","current":-53.785901,"percent":0,"low":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"high":-23.913403,"avg":-32.410788,"sd":6.666018,"marketCap":10540293438},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438}],"updateTime":1788138741289},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","BK4081","06938","EMA","EMA.AU","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112507773","title":"RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1112507773","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112507773?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:47","pubTimestamp":1778492820,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156882324","title":"RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1156882324","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156882324?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:44","pubTimestamp":1778492646,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240237","title":"Suzhou Ribo submits EMA Phase 2b trial application for vortosiran in VTE","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634240237?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:41","pubTimestamp":1778492465,"startTime":"0","endTime":"0","summary":"Suzhou Ribo submitted a Phase 2b clinical trial application to EMA for vortosiran  to prevent venous thromboembolism.Filing adds to vortosiran clinical program across thromboembolic cardiovascular indications; Phase 2a coronary artery disease study in Europe completed, Phase 2b atrial fibrillation CTA submitted to EMA in April 2026.Vortosiran targets factor XI via siRNA, aiming to reduce clot risk with lower bleeding risk than current anticoagulants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 11, 2026, and is solely responsible for the informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLc4Ct8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109213236","title":"RIBOLIFE-B Maintains 170.55 Million Issued Shares in April; Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1109213236","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109213236?lang=en_us&edition=fundamental","pubTime":"2026-05-07 17:23","pubTimestamp":1778145801,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) filed its Monthly Return for the period ended 30 April 2026, showing no changes in share capital structure. Authorised and Issued Share Capital   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633191371","title":"Ribo, Boehringer advance siRNA MASH drug program to third milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2633191371","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633191371?lang=en_us&edition=fundamental","pubTime":"2026-05-07 13:42","pubTimestamp":1778132570,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science disclosed a third key milestone under its siRNA collaboration with Boehringer Ingelheim to develop a potential treatment for metabolic dysfunction-associated steatohepatitis .No clinical study results were presented, with update focused on program progression and handoff for Boehringer Ingelheim to continue development.Milestone signals continued advancement of liver-targeted RNAi approach aimed at expanding future treatment options for MASH, a large and growing market with limited effective therapies.Update reinforces strategic value of Ribo’s liver-delivery platform as a partnering asset, supporting its positioning as a research and development partner for global drugmakers through 2026 and beyond.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9pLcCt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633918737","title":"Ribo and Boehringer Ingelheim Further Progress Their Sirna Program for Metabolic Dysfunction-Associated Steatohepatitis (Mash)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633918737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633918737?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:21","pubTimestamp":1778066485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nTUA6Z72ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175594296","title":"Hong Kong Stock Announcement Highlights | TESSON HOLDINGS Subsidiary Signs MOU with DST to Establish JV for Hong Kong New Energy Charging and Battery Swap Network, First Phase to Build 10 Multi-Functional Stations","url":"https://stock-news.laohu8.com/highlight/detail?id=1175594296","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175594296?lang=en_us&edition=fundamental","pubTime":"2026-05-06 09:14","pubTimestamp":1778030064,"startTime":"0","endTime":"0","summary":"Major Developments: LEADS BIOLABS-B (09887) will prioritize the clinical development of LBL-047 for Sjögren's syndrome, systemic lupus erythematosus, and dermatomyositis. ASCLETIS-B (01672) will...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1161","BK1574","BK4585","HK0000252160.HKD","159875","HK0000500386.USD","160640","BK1116","09887","HK0000252152.HKD","399941","000941.SH","BK4588","01201","06938","BK1515","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183303096","title":"RIBOLIFE-B Achieves Key Development Milestone in Liver Disease Collaboration with Boehringer Ingelheim","url":"https://stock-news.laohu8.com/highlight/detail?id=1183303096","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183303096?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:12","pubTimestamp":1778026340,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) has announced the successful achievement of the third key milestone in its research and development partnership with Boehringer Ingelheim (BI). The collaboration focuses on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134971944","title":"Ribo Life Science Reaches Third Milestone in Pre-clinical siRNA Partnership with Boehringer Ingelheim","url":"https://stock-news.laohu8.com/highlight/detail?id=1134971944","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134971944?lang=en_us&edition=fundamental","pubTime":"2026-05-06 08:02","pubTimestamp":1778025764,"startTime":"0","endTime":"0","summary":"On 6 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the attainment of the third key milestone in its research collaboration with Germany-based Boehringer Ingelheim. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633654975","title":"Suzhou Ribo hits third research milestone in Boehringer liver disease collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2633654975","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633654975?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:52","pubTimestamp":1778025179,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science reached third key milestone in research collaboration with Boehringer Ingelheim focused on novel therapies for liver disease, including metabolic dysfunction-associated steatohepatitis .Program remained in preclinical stage as of May 6, 2026, positioning milestone as an R&D progress marker rather than a development or commercialization inflection point.Collaboration targeted pipeline expansion for MASH, a condition linked to fibrosis, cirrhosis, liver failure, liver cancer, affecting more than 200 million people globally.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLVpLRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120235638","title":"RIBOLIFE-B聚焦创新药管线，2025年营收小幅增长但仍录净亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1120235638","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120235638?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:10","pubTimestamp":1776417031,"startTime":"0","endTime":"0","summary":"苏州瑞博生物科技有限公司（RIBOLIFE-B，香港联交所股票代码：06938）公布截至2025年12月31日止年度业绩，并在报告期内于核酸药物研发管线上取得重要进展。公司实现全年收入约人民币1.485亿元（较2024年增长4.1%），但大规模研发投入及管理开支推动全年仍录得净亏损。 经营及财务表现...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628279222","title":"Suzhou Ribo Life Science publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2628279222","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628279222?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:40","pubTimestamp":1776415202,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science published 2025 annual report highlighting pipeline progress across cardiovascular, metabolic, renal, and liver programs.Phase 2 trial for core candidate vortosiran  was basically completed, reinforcing its positioning as an FXI-targeting siRNA with long duration of effect.China Phase 2 trial for RBD5044 began in February 2026 following January 2026 clearance, supporting broader development alongside ongoing European work.Partner-led PCSK9 program RBD7022  moved toward Phase 3 initiation in China, marking first in-house-originated asset set to enter Phase 3.Report flagged strategic expansion via a Madrigal collaboration valued at more than USD 4.4 billion, alongside progress in extra-hepatic delivery research targeting kidney, heart, and adipose tissue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL525421:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UAN","BK1161","BK4590","BK4093","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182190562","title":"RIBOLIFE-B Shares Surge Over 7% in Morning Session Following Successful Phase IIb Submission for Vortosiran in Stroke Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=1182190562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182190562?lang=en_us&edition=fundamental","pubTime":"2026-04-15 11:33","pubTimestamp":1776224004,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4588","BK4585","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135129754","title":"RIBOLIFE-B (06938) Submits Application for Phase 2b Trial of Core Product VORTOSIRAN in SPAF Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1135129754","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135129754?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:08","pubTimestamp":1776125301,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, Vortosiran (RBD4059), has successfully submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 2b trial...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627252464","title":"Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF","url":"https://stock-news.laohu8.com/highlight/detail?id=2627252464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627252464?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:00","pubTimestamp":1776124845,"startTime":"0","endTime":"0","summary":"Suzhou Ribo submitted Phase 2b clinical trial application to European Medicines Agency for Vortosiran in stroke prevention in atrial fibrillation.Vortosiran  targets factor XI via siRNA, aiming to reduce thromboembolic risk with lower bleeding risk than current anticoagulants.Company said Vortosiran Phase 2a trial in coronary artery disease in Europe has been completed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL6dkqmC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157500309","title":"RIBOLIFE-B Maintains Stable Share Capital in March; 2.11 Million Pre-IPO Options Remain Unexercised","url":"https://stock-news.laohu8.com/highlight/detail?id=1157500309","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157500309?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:05","pubTimestamp":1775725511,"startTime":"0","endTime":"0","summary":"For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172541363","title":"China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1172541363","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172541363?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:54","pubTimestamp":1775184869,"startTime":"0","endTime":"0","summary":"According to statistics from the NMPA and PharmaGO, the total business development value for domestic innovative drugs in the first quarter of 2026 exceeded $60 billion, surpassing the full-year 2024...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0540923850.HKD","BK1191","IE00BPRC5H50.USD","BK1161","LU0348783233.USD","BK1500","LU0348827113.USD","159992","BK1583","IE00B543WZ88.USD","LU1023057109.AUD","06160","LU0307460666.USD","LU0417516738.SGD","LU0348766576.USD","BK1588","LU2543165471.USD","LU0359202008.SGD","09995","LU0348825331.USD","09926","LU0359201612.USD","01877","LU1720050803.USD","LU0348784397.USD","LU0359201885.HKD","LU0588546209.SGD","LU0417516571.SGD","LU0634319403.HKD","01276","LU0348735423.USD","LU2476274720.SGD","BK1574","LU2488822045.USD","LU2778985437.USD","LU2399975544.HKD","BK1515","LU0348767384.USD","LU2328871848.SGD","LU2476274308.USD","LU1770034418.SGD","LU1961090484.USD","LU1794554557.SGD","LU1969619763.USD","LU1303224171.USD","LU0417516902.SGD","LU0561508036.HKD","LU1251922891.USD","06978","LU1719994722.HKD","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868063","title":"Shrinking Losses At Suzhou Ribo Life Science (SEHK:6938) Test Bearish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868063","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868063?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:19","pubTimestamp":1774523958,"startTime":"0","endTime":"0","summary":"Setting the Scene: Suzhou Ribo Life Science's Latest Numbers\nSuzhou Ribo Life Science (SEHK:6938) has posted another loss for FY 2025, with first half revenue of ¥103.8 million and a basic EPS loss of ¥0.68, while trailing twelve month revenue sits at ¥148.5 million against a TTM EPS loss of ¥2.11. Looking back, revenue has moved from ¥66.3 million in 1H 2024 to ¥76.3 million in 2H 2024 and then to ¥103.8 million in 1H 2025, while basic EPS losses over these halves have gone from ¥1.07 to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/shrinking-losses-at-suzhou-ribo-life-science-sehk6938-test-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199028891","title":"RIBOLIFE-B (06938) Proposes Adoption of H Share Option Scheme and H Share Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1199028891","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199028891?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:55","pubTimestamp":1774450531,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on March 25, 2026, the board of directors resolved to propose the adoption of the company's H Share Option Scheme and H Share Incentive Plan (collectively referred...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":96,"code":"91000000","status":"200"}]}}